CCIA
KNSA icon

Campbell & Co Investment Adviser’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,869
Closed -$242K – 1245
2025
Q4 		$242K Sell
5,869
-32,248
-85% -$1.29M 0.01% 1019
2025
Q3 		$1.48M Buy
+38,117
New +$1.24M 0.11% 274
2025
Q2 		– Sell
-22,036
Closed -$489K – 1296
2025
Q1 		$489K Buy
+22,036
New +$454K 0.04% 684
2024
Q4 		– Sell
-10,550
Closed -$264K – 1212
2024
Q3 		$264K Sell
10,550
-1,960
-16% -$47.7K 0.02% 945
2024
Q2 		$234K Sell
12,510
-10,047
-45% -$188K 0.02% 914
2024
Q1 		$445K Sell
22,557
-625
-3% -$12.2K 0.04% 748
2023
Q4 		$407K Sell
23,182
-8,713
-27% -$143K 0.04% 810
2023
Q3 		$554K Sell
31,895
-25,379
-44% -$428K 0.07% 472
2023
Q2 		$806K Buy
57,274
+28,032
+96% +$375K 0.14% 232
2023
Q1 		$315K Sell
29,242
-36,288
-55% -$478K 0.06% 588
2022
Q4 		$982K Buy
65,530
+11,686
+22% +$170K 0.23% 105
2022
Q3 		$691K Buy
+53,844
New +$613K 0.16% 215

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Campbell & Co Investment Adviser's KNSA Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2026, closing a stake of 5,869 shares — an estimated $242K sold.

Campbell & Co Investment Adviser first reported a position in KNSA in Q3 2022 and held it in 12 quarters. The position peaked at $1.48M in Q3 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Kiniksa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 5,869 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $242K.
  • Campbell & Co Investment Adviser first reported a position in Kiniksa Pharmaceuticals in Q3 2022 and held it in 12 quarters.
  • Campbell & Co Investment Adviser's Kiniksa Pharmaceuticals position peaked at $1.48M in Q3 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.